Publications by authors named "Daniel Haller"

Claim this Profile
A
A stationary phase-specific bacterial green light sensor for enhancing metabolite production.
John T Lazar, Daniel J Haller, Abbas Ghaddar, Jae J Kim, Kevin Yang

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling biochemical network reveals context-dependent feedback control and kinetic constraints in the envelope stress response.
Cristina S D Palma, Natalie Allen, Martynas Basevicius, Ha Do, Kevin Li, Daniel J Haller

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in Spo0A~P pulsing frequency control biofilm matrix deactivation.
Cristina S D Palma, Daniel J Haller, Jeffrey J Tabor, Oleg A Igoshin

PLoS Comput Biol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database.
Jean-Baptiste Bachet, Aimery de Gramont, Morteza Raeisi, Manel Rakez, Richard M Goldberg, Daniel G Haller

J Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optogenetic Control of B. subtilis Gene Expression Using the CcaSR System.
Daniel J Haller, Sebastian M Castillo-Hair, Jeffrey J Tabor

Methods Mol Biol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programming Probiotics: Diet-Responsive Gene Expression and Colonization Control in Engineered .
Deniz Durmusoglu, Daniel J Haller, Ibrahim S Al'Abri, Katie Day, Carmen Sands

ACS Synth Biol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Particulate matter composition drives differential molecular and morphological responses in lung epithelial cells.
Sean M Engels, Pratik Kamat, G Stavros Pafilis, Yukang Li, Anshika Agrawal, Daniel J Haller

PNAS Nexus· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Particulate matter composition drives differential molecular and morphological responses in lung epithelial cells.
Sean M Engels, Pratik Kamat, G Stavros Pafilis, Yukang Li, Anshika Agrawal, Daniel J Haller

bioRxiv· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Claire Gallois, Qian Shi, Jeffrey P Meyers, Timothy Iveson, Steven R Alberts, Daniel G Haller

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Method of Inducible Directed Evolution to Evolve Complex Phenotypes.
Ibrahim S Al'Abri, Zidan Li, Daniel J Haller, Nathan Crook

Bio Protoc· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inducible directed evolution of complex phenotypes in bacteria.
Ibrahim S Al'Abri, Daniel J Haller, Zidan Li, Nathan Crook

Nucleic Acids Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance).
Jai N Patel, Chen Jiang, Kouros Owzar, Flora Mulkey, Jasmine A Luzum, Daniel G Haller

Pharmacogenet Genomics· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.
Zhaohui Jin, Jesse G Dixon, Jack M Fiskum, Hiral D Parekh, Frank A Sinicrope, Daniel Haller

J Natl Cancer Inst· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Chemoradiotherapy for Older Patients With Esophageal Cancer.
Jennifer R Eads, Daniel G Haller

JAMA Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients.
Ofer Margalit, Ben Boursi, Manel Rakez, André Thierry, Greg Yothers, Daniel G Haller

Clin Colorectal Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Anna D Wagner, Axel Grothey, Thierry Andre, Jesse G Dixon, Norman Wolmark, Daniel G Haller

J Natl Cancer Inst· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Romain Cohen, Julien Taieb, Jack Fiskum, Greg Yothers, Richard Goldberg, Daniel Haller

J Clin Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204).
A Bapsi Chakravarthy, Fengmin Zhao, Neal J Meropol, Patrick J Flynn, Lynne I Wagner, Daniel G Haller

Oncologist· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.
David K Lau, Matthew Burge, Amitesh Roy, Ian Chau, Daniel G Haller

Expert Rev Anticancer Ther· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.
Emerson Y Chen, Charles D Blanke, Daniel G Haller, Al B Benson, Tomislav Dragovich

Am J Clin Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted therapy for metastatic colorectal cancer.
Timothy J Price, Monica Tang, Peter Gibbs, Daniel G Haller, Marc Peeters

Expert Rev Anticancer Ther· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.
Monica Tang, Timothy Jay Price, Jeremy Shapiro, Peter Gibbs, Daniel G Haller

Expert Rev Anticancer Ther· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
Charles S Fuchs, Donna Niedzwiecki, Harvey J Mamon, Joel E Tepper, Xing Ye, Daniel G Haller

J Clin Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.
Demetris Papamichael, Lindsay A Renfro, Christiana Matthaiou, Greg Yothers, Leonard Saltz, Daniel G Haller

J Geriatr Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective.
Neil Lineberry, Jesse A Berlin, Bernadette Mansi, Susan Glasser, Michael Berkwits, Daniel Haller

BMJ· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis